Literature DB >> 25325801

Ethical justifications for access to unapproved medical interventions: an argument for (limited) patient obligations.

Mary Jean Walker1, Wendy A Rogers, Vikki Entwistle.   

Abstract

Many health care systems include programs that allow patients in exceptional circumstances to access medical interventions of as yet unproven benefit. In this article we consider the ethical justifications for-and demands on-these special access programs (SAPs). SAPs have a compassionate basis: They give patients with limited options the opportunity to try interventions that are not yet approved by standard regulatory processes. But while they signal that health care systems can and will respond to individual suffering, SAPs have several disadvantages, including the potential to undermine regulatory and knowledge-generation structures that constitute significant public goods. The "balance" between these considerations depends in part on how broadly SAPs are used, but also on whether SAPs can be made to contribute to the generation of knowledge about the effects of health interventions. We argue that patients should usually be required to contribute outcome data while using SAPs.

Entities:  

Keywords:  end-of-life issues; experimental therapies; health care delivery; patient rights; regulatory issues; research ethics; special access

Mesh:

Year:  2014        PMID: 25325801     DOI: 10.1080/15265161.2014.957416

Source DB:  PubMed          Journal:  Am J Bioeth        ISSN: 1526-5161            Impact factor:   11.229


  13 in total

1.  Right-to-try laws and individual patient "compassionate use" of experimental oncology medications: A call for improved provider-patient communication.

Authors:  Michael Hoerger
Journal:  Death Stud       Date:  2015-08-27

2.  Innovative Practice, Clinical Research, and the Ethical Advancement of Medicine.

Authors:  Jake Earl
Journal:  Am J Bioeth       Date:  2019-06       Impact factor: 11.229

3.  Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study.

Authors:  Agnes Vitry; Tuan Nguyen; Vikky Entwistle; Elizabeth Roughead
Journal:  J Pharm Policy Pract       Date:  2015-10-19

Review 4.  Phage Therapy: Combating Infections with Potential for Evolving from Merely a Treatment for Complications to Targeting Diseases.

Authors:  Andrzej Górski; Ryszard Międzybrodzki; Beata Weber-Dąbrowska; Wojciech Fortuna; Sławomir Letkiewicz; Paweł Rogóż; Ewa Jończyk-Matysiak; Krystyna Dąbrowska; Joanna Majewska; Jan Borysowski
Journal:  Front Microbiol       Date:  2016-09-26       Impact factor: 5.640

5.  Ethics review in compassionate use.

Authors:  Jan Borysowski; Hans-Jörg Ehni; Andrzej Górski
Journal:  BMC Med       Date:  2017-07-24       Impact factor: 8.775

Review 6.  The Medical Devices Special Access Program in Canada: A Scoping Study.

Authors:  Roland K Maier; Devidas Menon; Tania Stafinski
Journal:  Healthc Policy       Date:  2018-02

7.  Ethical considerations in the care of encephalopathic neonates treated with therapeutic hypothermia.

Authors:  Monica E Lemmon; Courtney J Wusthoff; Renee D Boss; Lisa Anne Rasmussen
Journal:  Semin Fetal Neonatal Med       Date:  2021-06-12       Impact factor: 3.726

8.  Going "social" to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access.

Authors:  Tim K Mackey; Virginia J Schoenfeld
Journal:  BMC Med       Date:  2016-02-02       Impact factor: 8.775

9.  An analysis of common ethical justifications for compassionate use programs for experimental drugs.

Authors:  Kasper Raus
Journal:  BMC Med Ethics       Date:  2016-10-18       Impact factor: 2.652

10.  The Ebola clinical trials: a precedent for research ethics in disasters.

Authors:  Philippe Calain
Journal:  J Med Ethics       Date:  2016-08-29       Impact factor: 2.903

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.